Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Bevacizumab

3

XVI.bf Imaging: Tumoral cavitation

1
Last update : 02/01/2014
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Pazopanib
2
Sorafenib
2
Sunitinib
2

Publications

Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors.
Journal of pediatric surgery 2015 Sep;50;1484-9 2015 Sep
Pulmonary hilar lymph node metastasis of breast cancer induced bronchopleural fistula and superior vena cava syndrome.
The American journal of case reports 2014 Nov 12;15;492-5 2014 Nov 12
New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know.
Cancer imaging : the official publication of the International Cancer Imaging Society 2014 Jul 23;14;26 2014 Jul 23
Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.
Annals of oncology : official journal of the European Society for Medical Oncology 2012 May;23;1111-1120 2012 May
Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.
Cancer imaging : the official publication of the International Cancer Imaging Society 2012 Jun 29;12;225-35 2012 Jun 29
Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Mar 20;27;1405-12 2009 Mar 20
Antiangiogenesis induced tumor cavitation in lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009 Dec;4;1573-5 2009 Dec
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004 Jun 01;22;2184-91 2004 Jun 01

Powered by

  • ^
  • Contact
  • Cookies
  • About